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Nasal High Flow Oxygen in Respiratory 
Failure
Eleni Ischaki, MD, Sotirios Malachias, MD, Spyros Zakynthinos, MD
A b s t R A C t
High flow nasal cannula system or nasal high flow oxygen is an oxygen delivery device 
which administers heated, humidified high flow oxygen with concentrations from 21% 
to 100% and with a flow rate up to 60 L/min in adults. It generates many physiologic 
effects to respiratory system with a lot of clinical applications. Indeed, greater comfort 
and tolerance, more effective oxygenation, and improved breathing pattern with in-
creased tidal volume and decreased respiratory rate and dyspnea have constantly been 
detected. Therefore, it can be used to improve cardiogenic pulmonary edema and 
hypoxemic respiratory failure of any cause, postoperatively, during post-extubation, 
as well as for palliative care.
I N t R O d U C t I O N
Oxygen in patients with hypoxemia is traditionally delivered either through low-flow 
devices (such as nasal cannula, non-rebreathing masks, and masks with reservoir bags) 
or through high-flow systems (such as Venturi masks). Low-flow devices deliver varying 
levels of fraction of inspired oxygen (FiO2) depending on the patient’s breathing pattern, 
peak inspiratory flow rate, delivery system and mask characteristics. High-flow devices 
provide a more constant FiO2 but they are less well tolerated than nasal cannula and are 
dislodged more easily. Heating and humidifying of inspired oxygen is limited with both 
low- and high- flow devices, especially in maximal flow rates. Additionally, at high 
patient’s inspiratory flow rates entrained room air dilutes the oxygen and lowers FiO2.
An alternative to conventional oxygen therapy is the high flow nasal cannula (HFNC) 
system [or nasal high flow oxygen (nHFO) therapy], which delivers FiO2 from 21% to 
100% with a flow rate up to 60 L/min in adults. The device consists of an air/oxygen 
blender connected through an active heated humidifier to the nasal cannula of large 
diameter, through a single limb, heated, inspiratory circuit. It allows adjustment of 
the FiO2 independently from the setting flow rate so that the patient is given a heated, 
humidified high flow oxygen, above its maximum inspiratory flow providing thus with 
confidence about the real FiO2 being delivered to the patient. Several studies have shown 
that HFNC generates a low level of positive airway pressure, improves oxygenation, 
increases the end-inspiratory lung volume, reduces airway resistance, increases func-
tional residual capacity (FRC) and flush nasopharyngeal dead space, thus helping to 
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manage the acute respiratory failure from all causes. It is also 
better tolerated and more comfortable than conventional oxygen 
treatment. Finally, pulmonary defense mechanisms are restored. 
Herein, we review the literature for the physiologic effects of 
HFNC, its clinical applications in adults and the advantages or 
disadvantages of its use.
Nasal High Flow Oxygen (nHFO) Therapy is Associated 
with the Generation of Significant Positive Airway 
Pressure in Volunteers which is Flow Dependent and 
also Dependent on Whether the Patient is Breathing 
With Mouth Open or Closed
In a group of 10 healthy volunteers, a 10-French catheter 
was placed into the oropharynx and nHFO was initiated. Phar-
yngeal pressures were recorded during intranasal flows from 
0 to 60 L/min with the mouth open and closed. As flow rates 
increased, expiratory pharyngeal pressure (EPP) increased 
also with both the mouth open and closed (P<0.001). EPPs 
were statistically higher (P<0.001) with the mouth closed 
compared with the mouth open. EPP tended to be higher 
among females than male subjects for both open (P<0.05) 
and closed (P<0.001) measurements. Female’s facial features 
with smaller nares may have attributed to their higher EPPs 
because of less leak. Inspiratory pharyngeal pressures (IPP) 
increased with increasing flow rates with both the mouth open 
and closed (P<0.001) and although the IPP was significantly 
higher than no flow at 20, 40 and 60 L/min for both mouth 
open and closed measurements, values were not statistically 
different between open and closed mouth. IPPs were statisti-
cally different between genders with the mouth open (P<0.05) 
but not with the mouth closed. The authors concluded that 
nHFO generates significant expiratory positive pressure which 
appears to be flow dependent and influenced by whether the 
person is breathing with mouth open or closed. nHFO could 
be used as an alternative to non-invasive ventilation as it may 
be a comfortable, requires less patient cooperation, whilst still 
providing high inspired oxygen levels and positive pressure 
(Groves N et al, Australian Critical Care 2007;20:126-131).
Warm and Humidified Air through Nasal High Flow 
Oxygen (nHFO) System Improves Lung Mucociliary 
Clearance in Patients with Bronchiectasis 
Patients with the diagnosis of idiopathic bronchiectasis 
underwent assessment of their mucociliary clearance from the 
retention of inhaled 99mTc-labelled polystyrene tracer particles, 
before (baseline) and after receiving warm and humidified air 
through nHFO system for 6 hours. Humidification resulted 
in significant and sustained enhancement of lung clearance 
(P=0.02 at 6 hours) compared with baseline assessment. After 
the end of the 6-hour treatment period with humidified air, the 
sputum wet weight was lesser, and after 7 days of treatment the 
number of coughs was slightly but non-significantly reduced. 
Although, differences were statistically non-significant, all lung 
function indices slightly improved following humidification 
compared with baseline assessment. The authors concluded that 
warm air humidification treatment improves lung mucociliary 
clearance in bronchiectatic patients (Hasani A et al, Chronic 
Respiratory Disease 2008; 5: 81–86).
In Cardiac Surgery Patients, the Mean Nasopharyngeal 
Pressure during Nasal High Flow Oxygen (nHFO) 
Increases as Flow Increases 
In 15 cardiac surgery patients, a 10-French catheter was 
inserted via the nose to nasopharynx and nHFO was started after 
extubation. Nasopharyngeal airway pressure measurements 
were then performed with the patient’s mouth open and closed, 
at flows of 30, 40, and50 L/min. Between mouth open and 
closed, there were statistically significant pressure differences 
at each flow. There was a positive linear relationship between 
flow and pressure, whilst the slope was lower with mouth open 
than with mouth closed. In the mouth-closed position, for every 
10 L/min increase in gas flow, the mean pressure increased by 
0.69 cmH2O (P = 0.01). In the mouth-open position, for every 
10 L/min increase in gas flow, the mean pressure increased 
by 0.35 cmH2O (P=0.03). The resistance to expiration that is 
generated by the patient breathing out against the continuous 
incoming gas flow is the main mechanism for this positive 
airway pressure. The authors concluded that in cardiac surgery 
patients, there was a positive linear relationship between flow 
and airway pressure during nHFO which may extend the role 
of oxygen therapy by delivering low-level positive airway 
pressure (Parke RL et al, Respir Care 2011;56:1151-1155).
High Flow Nasal Cannulas (HFNCs) Reduce 
Respiratory Rate and Improve Oxygenation by 
Increasing Both End-Expiratory Lung Volume and 
Tidal Volume and are Most Beneficial in Patients With 
Higher Body Mass Indices (BMIs)
Post-cardiac surgery patients with respiratory distress and 
PaO2/FiO2 ratio <300 requiring oxygen therapy were recruited. 
When compared with a low-flow oxygen device, oxygen 
through HFNC increased mean airway pressure (Paw) by 3.0 
cmH2O (P<0.001), the end-expiratory lung volume (EELV) 
by 25.6% (P<0.001) and the tidal volume (Vt) by 10.5% 
(P<0.001). Patient’s mouth, open or closed, did not affect EELV 
or Paw. A strong and significant correlation was found between 
Paw and EELV (r=0.7, P<0.001). The increased EELV and Vt 
resulted in improvement of PaO2/FiO2by 30.6% (P<0.001) even 
though 95% of patients were receiving an equal or lower FiO2 
while on HFNC than on low-flow oxygen. Additionally, with 
HFNC, respiratory rate was lowered by 3.4 bpm (P<0.001) 
and the Borg dyspnea score by 0.8 points (P=0.023) compared 
to low-flow oxygen. Body mass index (BMI) significantly 
influenced the positive effect of HFNC on EELV (P<0.001) 
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with higher BMI resulting in greater improvements of EELV. 
The authors concluded that HFNC may be a useful treatment 
option for post-cardiac surgery patients experiencing respira-
tory dysfunction, generating clinically relevant increases in 
Paw, EELV and Vt, particularly in patients with higher BMIs. 
These changes are associated with reduced respiratory rate, 
less dyspnea, and improved oxygenation (Corley A et al, Br 
J Anaesth2011;107:998-1004). 
High Flow Nasal Cannula (HFNC) has a Beneficial 
Effect on Respiratory Rate, Heart Rate, Dyspnea Score 
and Oxygenation Indices in ICU Patients With Acute 
Respiratory Failure Without Any Significant Side Effects
Efficiency, safety and outcome of oxygen therapy with 
HFNC were evaluated in ICU patients with acute respiratory 
failure and signs of respiratory distress who were previously 
treated with oxygen through a non-rebreathing mask. Use of 
HFNC was associated with a significant reduction in respiratory 
rate, heart rate, dyspnea score, supraclavicular retraction and 
thoraco-abdominal asynchrony (both being signs of respiratory 
distress), and a significant improvement in pulse oximetry. 
These improvements were seen within the first 30 minutes 
after the beginning of HFNC (except for the heart rate which 
improved within the first 6 hours) and lasted throughout the 
study period. The PaO2/FiO2 ratio was significantly improved 
at 1 and 24 h when compared with the value observed before 
use of HFNC (P =0.036) without any significant increase in 
pH (P =0.87) and PaCO2 (P =0.77) on arterial blood gases 
throughout the study period. No unexpected side effect was 
reported and intolerance was never a cause of HFNC cessation. 
Average duration of HFNC use was 2.8 ± 1.8 days (maximum 
7 days). A total of 24% of patients required intubation and 
invasive mechanical ventilation while on HFNC. After HFNC 
beginning, predictors of HFNC failure were a higher respira-
tory rate at 30 min (29.1±3.8 vs. 24.6±5.8; P =0.05), lower 
SpO2 at 15 and 30 min (92.7±10.1 vs. 98.4±2.2, P =0.007 and 
94.2±7.8vs. 97.8±2.6, P =0.0035, respectively), a lower PaO2/
FiO2 ratio at 1 h (90.7±33.1 vs. 200.6±111.7; P =0.008) and a 
greater proportion of thoraco-abdominal asynchrony at 15 min. 
The authors concluded that HFNC shows a favorable effect 
on clinical signs and oxygenation in critical care patients with 
acute respiratory failure. An early lack of decrease in respira-
tory rate and persistence of thoraco-abdominal asynchrony are 
early and simple indicators of HFNC failure (Sztrymf B et al, 
Intensive Care Med 2011;37:1780–1786).
Nasal High Flow Oxygen (nHFO) May be More 
Effective Than Standard Oxygen Through 
Unhumidified High-Flow Face Mask in Treating Mild 
to Moderate Hypoxemic Respiratory Failure Reducing 
the Need for Non-Invasive Ventilation 
Patients with mild to moderate hypoxemic respiratory 
failure were randomly allocated to receive humidified high-
flow oxygen via either nHFO system or unhumidified high 
flow face mask (standard face mask). More nHFO than stand-
ard face mask patients succeeded on their allocated therapy 
(P=0.006). The rate of noninvasive ventilation in the nHFO 
group was 10%, compared with 30% in the standard face mask 
group (P=0.10). Although baseline SpO2 was similar between 
the two treatment groups, the nHFO group had significantly 
fewer desaturations compared to the standard face mask group 
(42% vs 71%, respectively; P=0.009).PaO2/FiO2 ratio, ICU 
and hospital stay did not differed significantly between the 
two groups. The authors concluded that the nHFO system was 
more successful than the standard face mask in the treatment 
of mild to moderate hypoxemic respiratory failure. They at-
tributed the difference in the use of noninvasive ventilation 
to the positive pressure delivered by the nHFO system (Parke 
RL et al, Respir Care 2011;56:265–270).
Nasal High Flow Oxygen (nHFO) Can Improve Arterial 
Blood Gases and Dyspnea in Patients With Refractory 
Hypoxemia Due to Acute Pulmonary Edema Secondary 
to Heart Failure
Patients with respiratory failure due to acute pulmonary 
edema who were initially treated with non-invasive ventilation 
or developed refractory hypoxemia to conventional oxygena-
tion methods, received oxygen through high flow nasal cannula 
(HFNC) at high flow rates (60L/min). After 24 h of treatment 
with the HFNC system PaO2, SaO2, heart rate and respira-
tory rate showed significant improvement (P<0.001, P=0.42, 
P=0.024, and P=0.002, respectively) without any deterioration 
in PaCO2values. In patients with moderate or severe dyspnea, 
the intensity of the condition improved significantly, becoming 
mild in 80% of the patients. The HFNC system was well toler-
ated with only 2 patients feeling tracheal discomfort, which 
was self-limited. The mean duration of treatment with HFNC 
was 62.4±21.4 hours. The authors concluded that the use of 
HFNC system is a good alternative to traditional oxygenation 
systems for the treatment of patients with refractory hypox-
emia due to acute pulmonary edema secondary to acute heart 
failure. The system is well tolerated and produces significant 
clinical arterial blood gases improvements (Carratala Perales 
JM et al, Rev Esp Cardiol 2011;64:723–725).
During Bronchoscopy, Both the Venturi Mask and 
HFNC at Flow Rate of 40 L/Min Behave in a Similar 
Way, but HFNC at 60 L/min Flow Produce Better 
Oxygenation and Could be Used in Patients With Mild 
Respiratory Dysfunction
Patients without respiratory failure (SpO2 ≥90%) undergo-
ing fiberoptic bronchoscopy and bronchoalveolar lavage (BAL) 
fluid collection as a diagnostic tool for pulmonary disease, 
were randomly assigned to 3 groups of oxygen administration 
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during the procedure: Venturi mask at 40L/min (V40), HFNC 
at 40L/min (N40) and HFNC at 60L/min (N60). FiO2 was set 
to 50% in all 3 groups. At the end of bronchoscopy, in the N60 
group, PaO2/FiO2and SpO2 were larger than those in V40 and 
N40 groups, while in V40 and N40 they did not differ. No 
differences in pH, PaCO2, heart rate and mean arterial pressure 
values were found among the 3 groups. Ten minutes after the 
end of bronchoscopy, SpO2 between N60 andV40 was the 
only detected significant difference. There was no difference 
in the level of comfort among the three groups (P =0.569). In 
an extra group of normal volunteers, end-expiratory airway 
pressure amounted to 3.6 (2.4–4.0) cmH2O using HFNC at 
flow rates of 60 L/min while no measurable end-expiratory 
pressure was detected with HFNC at 40L/min and Venturi mask 
at 40L/min. The authors concluded that during bronchoscopy, 
where hypoxemia is commonly found, HFNC at flow rates of 
60 L/min could protect patients to a larger extent, especially 
those with mild respiratory dysfunction (Lucangelo U et al, 
Crit Care Res Pract 2012;20:365-382). 
The Use of nHFO is Associated With a Lower 
Respiratory Rate, Higher Oxygen Saturation, and 
Improved Comfort Scales Compared to Conventional 
Oxygen Therapy in a Group of Patients With 
Hypoxemia in the Emergency Department 
To all patients with hypoxemic respiratory failure who 
presented at the emergency department and remained dyspneic 
despite aggressive conventional treatment in parallel with 
administration of supplemental oxygen through face mask, 
oxygen through HFNC was initiated. Compared to the variables 
at hour zero, while receiving oxygen therapy through face mask, 
HFNC was associated with a significant decrease in dyspnea 
intensity in both the Borg score [6 (5-7) vs 4 (3-4); P<0.05] 
and the Visual Analog Scale [7 (5-8) vs 5 (2-6); P<0.05] as 
early as 15 min. After 15 min, respiratory rate decreased sig-
nificantly (P<0.05) and SpO2 increased significantly (P<0.01). 
These beneficial effects were maintained throughout the next 
hour with fewer subjects on HFNC exhibiting clinical signs of 
respiratory distress (P<0.03). All patients but one stated greater 
comfort with HFNC than with the face mask and only two of 
them declared having been disturbed by the noise. Objective 
sound level measurement indicated that HFNC generated the 
same noise as face mask (55 dB vs 50 dB respectively). The 
great majority of caregivers (76%) declared preferring HFNC 
as it seems more efficient than conventional oxygen therapy 
through the face mask and because patients feel more comfort-
able with this device. The authors concluded that HFNC could 
constitute a first line therapy for selected patients presenting to 
the emergency department with acute respiratory failure with 
rapid and sustained alleviation of dyspnea and improvement 
in oxygenation while it seems to be well tolerated and more 
comfortable to use than conventional oxygen therapy via a 
face mask (Lenglet H et al, Respir Care 2012;57:1873–1878). 
HFNC Can Provide Adequate Oxygenation for Do-
Not-Resuscitate (DNR) Patients With Hypoxemic 
Respiratory Failure and May be an Alternative to Non-
Invasive Ventilation
Patients with do-not-resuscitate (DNR) resuscitation status 
who develop respiratory failure are commonly treated with 
noninvasive ventilation. In this study, nHFO was initiated to 
those patients instead of noninvasive ventilation and it was 
found that breathing frequency decreased from 30.6 breaths/
min to 24.7 breaths/min (P <0.001) and mean oxygen saturation 
improved from 89.1% to 94.7% (P <0.001), without signifi-
cant difference on PaCO2 values. 18% of subjects escalated 
to noninvasive ventilation, while 82% were maintained on 
nHFO until improvement or withdrawal of support. Among 
the 18% who progressed to noninvasive ventilation, 67% died, 
versus 58% among those who did not receive noninvasive 
ventilation (P=0.72). nHFO was well tolerated, with no epi-
sodes of nasal bleeding or facial skin breakdown. The authors 
concluded that nHFO can provide adequate oxygenation for 
many patients with hypoxemic respiratory failure, and may 
be an alternative to noninvasive ventilation for DNR patients 
or patients who decline intubation (Peters SG et al, Respir 
Care 2013;58:597–600).
Nasal High Flow Oxygen (nHFO) Increases Functional 
Residual Capacity, Regardless of Body Position. With 
nHFO Administration, Regional Ventilation is More 
Homogenous in Prone Position, While in Supine 
Position Ventilation was Higher in the Ventral Lung 
Regions 
Oxygen through HFNC at a constant flow of 40 L/min was 
applied to 20 healthy volunteers and regional ventilation was 
estimated through electrical impedance tomography (EIT). 
Good correlations have been found between changes in end-
expiratory lung impedance (EELI) and changes in EELV. In 
supine position, global EELI increased by 1.26 units (P<0.001) 
when HFNC was applied, compared to ambient air breathing 
and decreased by 1.30 (P<0.001) when the subject breathed 
ambient air again. In prone position, similar changes in global 
EELI with HFNC were observed. EELI increased by 0.87 units 
(P<0.001) during the HFNC application and decreased by 1.03 
units (P<0.001) when it stopped. In supine position, higher 
values of regional EELI were observed in the ventral versus 
dorsal lung regions while on HFNC compared to ambient air 
breathing (P<0.001). In prone position, a more homogeneous 
pattern of regional EELI variation was observed, with a non-
significant increase in EELI in the ventral regions versus dorsal 
regions. Breathing frequency decreased while on HFNC by a 
mean of 2.73 breaths/min (P=0.02) in supine position and by 
a mean of 7.89 breaths/min (P<0.001) in prone position. The 
authors concluded that administration of nHFO therapy may 
help to develop new management strategies for hypoxemic 
respiratory failure through significant increment of EELI, a 
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fact that suggests an increment of functional residual capacity 
in both supine and prone positions with simultaneous decre-
ment of the breathing frequency in both positions (Riera J et 
al, Respir Care 2013;58:589-596).
Compared with the Venturi Mask, nHFO Results 
in Better Oxygenation for the Same Set FiO2 
After Extubation, Better Patient Comfort, Fewer 
Desaturations and a Lower Reintubation Rate
A total of 105 patients mechanically ventilated for more 
than 24 hours were randomized after their extubation to 
Venturi mask or nHFO if the PaO2/FiO2 ratio was <300 at the 
end of spontaneous breathing trial. The PaO2/FIO2ratio was 
significantly higher with nHFO compared to Venturi mask at 
24 hours (287.2± 74.3mm Hg vs 247.4± 80.6 mm Hg; P =0.03) 
and at 48 hours (313.3±83.8 mm Hg vs 250.2±110.1 mm Hg; 
P =0.01).Respiratory rate was always significantly lower with 
the nHFO, with a mean difference of 4±1 breaths/min. Vital 
signs (heart rate and mean arterial blood pressure) did not differ 
between groups. Using a 10-point numerical rating scale (0=no 
discomfort to 10=maximum discomfort), nHFO compared to 
Venturi mask was associated with a lower discomfort related 
to mouth dryness (3.6±2.5 vs 5±3.1; P =0.016), throat dryness 
(2.7±2.4 vs 4.5±3.3; P =0.002), difficulty to swallow (2.5±2.6 
vs 4.1±3.4; P =0.007) and throat pain (1.7±2.1 vs 3.1±3.4; P 
=0.008) during the 48-h study period. Fewer patients in the 
nHFO group had episodes of oxygen desaturation, detected 
electronically (39.6% vs 75%; P<0.001) and by nurses (18.9% 
vs 51.9%; P<0.001). 7.5% of the patients on nHFO group 
developed post extubation respiratory failure requiring any 
form of ventilator support versus 34.6% in the control group 
(P <0.001). Specifically, fewer patients received non-invasive 
ventilation (P=0.04) and required endotracheal intubation (P 
<0.01) with the nHFO than with the Venturi mask. The authors 
concluded that as compared with the Venturi mask, the use 
of the nHFO system in the post-extubation period results in 
better oxygenation for the same set FIO2. In addition, nHFO 
decreases respiratory rate, while improving patient comfort 
and reducing episodes of oxygen desaturation. Also nHFO 
in the post-extubation period is associated with less need for 
any kind of ventilator support (Maggiore S et al, Am J Respir 
Crit Care Med 2014;190:282-288).
Nasal High Flow Oxygen (nHFO) Improves Survival 
in Patients With Acute Hypoxemic Respiratory Failure 
But it Does not Improve Intubation Rates
A total of 310 patients with acute hypoxemic respiratory 
failure were randomized to receive oxygen therapy either 
through a non-rebreathing face mask, nHFO or they received 
non-invasive mechanical ventilation. The intubation rate at day 
28 was 38% in the nHFO group, 47% in the non-rebreathing 
mask group, and 50% in the non-invasive ventilation group 
(P = 0.18).The intervals between enrollment and intubation, 
as well as the reasons for intubation, did not also differ sig-
nificantly among the 3 groups. In the subgroup of patients 
with a PaO2/FiO2 of 200 mmHg or less, the intubation rate 
was significantly lower in the nHFO group than in the other 
2 groups. The hazard ratio for death at 90 days was 2.01 in 
the non-rebreathing mask group as compared with the nHFO 
group (P=0.046) and 2.50 in the non-invasive ventilation group 
as compared with the nHFO group (P=0.006).The number of 
ventilator-free days at day 28 was significantly higher in the 
nHFO group than in the other two groups(24±8 days, vs 22±10 
in the standard oxygen group and 19±12 in the non-invasive 
ventilation group; P=0.02 for all comparisons).The authors 
concluded that treatment with nHFO improved the survival 
rate among patients with acute hypoxemic respiratory failure, 
even though no difference in the intubation rate was observed 
with nHFO therapy, as compared with standard oxygen therapy 
through a non-rebreather mask or non-invasive ventilation 
(Frat JP et al, N Engl J Med 2015;372:2185-2196).
During Intubation, nHFO Significantly Improves 
Preoxygenation and Reduces the Prevalence of Severe 
Hypoxemia Compared With Non-Rebreathing Bag 
Reservoir Facemask, Thus Potentially Improving 
Patient Safety 
A total of 101 adult patients requiring endοtracheal intuba-
tion in an ICU were divided to receive preoxygenation for 3 
minutes either through a non-rebreathing face mask or through 
nHFO cannula. The decrease in SpO2 during intubation was 
greater in the face mask group as evidenced by the lowest val-
ues of SpO2 reached in each group (94% vs 100%; P<0.0001). 
These lowest values were received at the end of preoxygenation 
period. After adjustment for significant baseline covariates, 
such as reason for intubation or difficulty of intubation, the 
difference remained significant (94% vs 99%; P=0.007). The 
prevalence of severe hypoxemia, defined by a SpO2 less than 
80% during the procedure, was significantly lower in the nHFO 
group (2% vs 14%; P=0.03). In multivariate analysis, preoxy-
genation with nHFO was an independent protective factor of 
the occurrence of severe hypoxemia (P=0.037). The authors 
concluded that use of nHFO for preoxygenation significantly 
reduced the prevalence of severe hypoxemia during intubation 
compared with face mask in ICU patients (Miguel-Montanes 
R et al, Crit Care Med 2015;43:574-583).
HFNC was not Shown to Reduce the Need  
for Non-Invasive or Invasive Mechanical  
Ventilation in Emergency Department Subjects  
With Acute Respiratory Distress Compared With 
Standard Oxygen Therapy Although it Reduced  
the Need for Escalation of Oxygen Therapy Within  
the First 24 h of Admission 
Patients presenting at the emergency department with res-
piratory failure (SpO2 ≤92% on air or ≤90% on air if there is a 
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known history of CO2 retention) were randomized to receive 
oxygen through HFNC or through standard methods (Venturi 
mask, Hudson mask, nasal prongs). There was no difference 
between the groups in the proportion of subjects requiring non-
invasive ventilation or invasive positive-pressure ventilation in 
the emergency department: 3.6% in the HFNC group vs 7.3% 
in the standard O2 group (P=0.16).There was also no difference 
in the emergency department or hospital length of stay, with 
a median of 4.5 hours in the HFNC group vs 4.9 hours in the 
standard O2 group (P=0.32) and 5.0 days in the HFNC group vs 
5.6 days in the standard oxygen therapy (P=0.43), respectively. 
Mortality at 90 days was similar between the 2 study groups: 
21.2% in the HFNC group compared to 17.4% in the standard 
oxygen delivery group (P=0.40). Nose or mouth dryness was 
significantly lesser in HFNC group (29.8% vs 45.3%; P=0.046). 
The authors concluded that HFNC was not shown to reduce 
the need for mechanical ventilation in the emergency depart-
ment for subjects with acute respiratory distress compared 
with standard oxygen therapy. However, HFNC may reduce 
the need for escalation of oxygen therapy within the first 24 
h of admission (Jones PG et al, Respir Care2015 Nov 17. pii: 
respcare.04252. [Epub ahead of print]).
Other articles
Nasal high flow oxygen (nHFO) has also been investigated 
or reviewed in the following articles: 1) Diaz-Lobato S et al, 
Respir Care 2013;58:e164-e167; 2) Chatila W et al, Chest 2004; 
126:1108–1115; 3) Spoletini G et al, Chest 2015; 148: 253-261; 
and 4) Gotera C et al, Rev Port Pneumol 2013;19:217-227.
C O N C L U s I O N
Benefits of nasal high flow oxygen (nHFO) over con-
ventional oxygen therapy have been reported in almost all 
studies. Indeed, greater comfort and tolerance, more effective 
oxygenation, and improved breathing pattern with increased 
tidal volume and decreased respiratory rate and dyspnea have 
constantly been documented. Therefore, nHFO can be used as an 
intermediate therapy to improve cardiogenic pulmonary edema 
and hypoxemic respiratory failure of any cause, postoperatively, 
during post extubation, as well as for palliative care. However, 
in order to make recommendations, there is a great need for 
further research with physiologic and randomized controlled 
studies to determine its clinical use in relation to traditional 
methods of oxygenation and mechanical ventilation.
